Results 11 to 20 of about 19,626 (100)
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Journal of Clinical Oncology, 2019 PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non–small-cell lung cancer (NSCLC).N. Ready, M. Hellmann, M. Awad, G. Otterson, M. Gutierrez, J. Gainor, H. Borghaei, J. Jolivet, L. Horn, M. Mates, J. Brahmer, I. Rabinowitz, P. Reddy, J. Chesney, J. Orcutt, D. Spigel, M. Reck, K. O'Byrne, L. Paz-Ares, Wenhua Hu, K. Zerba, Xuemei Li, B. Lestini, W. Geese, J. Szustakowski, G. Green, Han Chang, S. Ramalingam +27 moresemanticscholar +1 more sourceS(+)-(2E)-N-(2-Hydroxypropyl)-3-Phenylprop-2-Enamide (KM-568): A Novel Cinnamamide Derivative with Anticonvulsant Activity in Animal Models of Seizures and Epilepsy
International Journal of Molecular Sciences, 2020 Epilepsy is one of the most frequent neurological disorders affecting about 1% of the world’s human population. Despite availability of multiple treatment options including antiseizure drugs, it is estimated that about 30% of seizures still remain ...Agnieszka Gunia-Krzyżak, Ewa Żesławska, K. Słoczyńska, D. Żelaszczyk, Aleksandra Sowa, P. Koczurkiewicz-Adamczyk, Justyna Popiół, W. Nitek, E. Pękala, H. Marona +9 moresemanticscholar +1 more sourceDeclining complication rates with flow diversion of anterior circulation aneurysms after introduction of the Pipeline Flex: analysis of a single-institution series of 568 cases.
Journal of Neurosurgery, 2018 OBJECTIVEThe second-generation Pipeline embolization device (PED), Flex, has several design upgrades, including improved opening and the ability to be resheathed, in comparison with the original device (PED classic). The authors hypothesized that Flex is G. Colby, M. Bender, Li-Mei Lin, N. Beaty, J. Caplan, B. Jiang, E. Westbroek, Bijan K. Varjavand, J. Campos, Judy Huang, R. Tamargo, A. Coon +11 moresemanticscholar +1 more sourceAbstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
Clinical Trials, 2018 Background: Several studies have demonstrated the potential clinical utility of TMB as a biomarker of immune checkpoint blockade in multiple tumor types, including lung cancer.Suresh S. Ramalingam, M. Hellmann, M. Awad, H. Borghaei, J. Gainor, J. Brahmer, D. Spigel, Martin Reck, Kenneth J. O'Byrne, L. Paz-Ares, K. Zerba, Xuemei Li, W. Geese, George Green, B. Lestini, J. Szustakowski, Han Chang, N. Ready +17 moresemanticscholar +1 more sourceLongitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results
Alzheimer's &Dementia, Volume 20, Issue 5, Page 3525-3542, May 2024.Abstract INTRODUCTION
Effective longitudinal biomarkers that track disease progression are needed to characterize the presymptomatic phase of genetic frontotemporal dementia (FTD). We investigate the utility of cerebral perfusion as one such biomarker in presymptomatic FTD mutation carriers.Maurice Pasternak, Saira S. Mirza, Nicholas Luciw, Henri J. M. M. Mutsaerts, Jan Petr, David Thomas, David Cash, Martina Bocchetta, Maria Carmela Tartaglia, Sara B. Mitchell, Sandra E. Black, Morris Freedman, David Tang‐Wai, Ekaterina Rogaeva, Lucy L. Russell, Arabella Bouzigues, John C. van Swieten, Lize C. Jiskoot, Harro Seelaar, Robert Laforce Jr., Pietro Tiraboschi, Barbara Borroni, Daniela Galimberti, James B. Rowe, Caroline Graff, Elizabeth Finger, Sandro Sorbi, Alexandre de Mendonça, Chris Butler, Alex Gerhard, Raquel Sanchez‐Valle, Fermin Moreno, Matthis Synofzik, Rik Vandenberghe, Simon Ducharme, Johannes Levin, Markus Otto, Isabel Santana, Antonio P. Strafella, Bradley J. MacIntosh, Jonathan D. Rohrer, Mario Masellis, the GENetic Frontotemporal dementia Initiative (GENFI), Annabel Nelson, Martina Bocchetta, David Cash, David L Thomas, Emily Todd, Hanya Benotmane, Jennifer Nicholas, Kiran Samra, Rachelle Shafei, Carolyn Timberlake, Thomas Cope, Timothy Rittman, Alberto Benussi, Enrico Premi, Roberto Gasparotti, Silvana Archetti, Stefano Gazzina, Valentina Cantoni, Andrea Arighi, Chiara Fenoglio, Elio Scarpini, Giorgio Fumagalli, Vittoria Borracci, Giacomina Rossi, Giorgio Giaccone, Giuseppe Di Fede, Paola Caroppo, Pietro Tiraboschi, Sara Prioni, Veronica Redaelli, David Tang‐Wai, Ekaterina Rogaeva, Miguel Castelo‐Branco, Morris Freedman, Ron Keren, Sandra Black, Sara Mitchell, Christen Shoesmith, Robart Bartha, Rosa Rademakers, Jackie Poos, Janne M. Papma, Lucia Giannini, Rick van Minkelen, Yolande Pijnenburg, Benedetta Nacmias, Camilla Ferrari, Cristina Polito, Gemma Lombardi, Valentina Bessi, Michele Veldsman, Christin Andersson, Hakan Thonberg, Linn Öijerstedt, Vesna Jelic, Paul Thompson, Tobias Langheinrich, Albert Lladó, Anna Antonell, Jaume Olives, Mircea Balasa, Nuria Bargalló, Sergi Borrego‐Ecija, Ana Verdelho, Carolina Maruta, Catarina B. Ferreira, Gabriel Miltenberger, Frederico Simões do Couto, Alazne Gabilondo, Ana Gorostidi, Jorge Villanua, Marta Cañada, Mikel Tainta, Miren Zulaica, Myriam Barandiaran, Patricia Alves, Benjamin Bender, Carlo Wilke, Lisa Graf, Annick Vogels, Mathieu Vandenbulcke, Philip Van Damme, Rose Bruffaerts, Koen Poesen, Pedro Rosa‐Neto, Serge Gauthier, Agnès Camuzat, Alexis Brice, Anne Bertrand, Aurélie Funkiewiez, Daisy Rinaldi, Dario Saracino, Olivier Colliot, Sabrina Sayah, Catharina Prix, Elisabeth Wlasich, Olivia Wagemann, Sandra Loosli, Sonja Schönecker, Tobias Hoegen, Jolina Lombardi, Sarah Anderl‐Straub, Adeline Rollin, Gregory Kuchcinski, Maxime Bertoux, Thibaud Lebouvier, Vincent Deramecourt, Beatriz Santiago, Diana Duro, Maria João Leitão, Maria Rosario Almeida, Miguel Tábuas‐Pereira, Sónia Afonso +155 morewiley +1 more sourceHypofractionated electron-beam radiation therapy for keloids: retrospective study of 568 cases with 834 lesions
Journal of Radiation Research, 2015 We aimed to analyze the outcomes of hypofractionated high-energy electron beam radiotherapy for the treatment of keloids. From February 1998 to January 2012, 568 patients with a total of 834 keloids underwent radiotherapy: 826 lesions with postoperative ...Jie Shen, X. Lian, Yuliang Sun, Xiaojun Wang, K. Hu, X. Hou, Shuai Sun, Junfang Yan, Lang Yu, Xiansong Sun, Wen-bo Li, Xinhai Wang, Qiu Guan, T. Pang, Fuquan Zhang +14 moresemanticscholar +1 more source